Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia
Community Acquired Pneumonia
About this trial
This is an interventional treatment trial for Community Acquired Pneumonia
Eligibility Criteria
Inclusion Criteria: Recent respiratory illness with signs and symptoms and chest X-ray consistent with the diagnosis of community-acquired pneumonia. Suitable candidate for oral antibiotic therapy and able to swallow large capsules intact If female, must be non-lactating and at no risk for pregnancy Exclusion Criteria: Other infections Other pulmonary diseases requirement multiple antibacterial medications or long duration of therapy History of hypersensitivity, allergic or adverse reactions to macrolide, ketolide, azalide or streptogramins Evidence of uncontrolled clinically significant disease, malignancy, or other abnormality Requirement of parenteral antimicrobial therapy for treatment of pneumonia Currently receiving or likely to receive any known inhibitors or inducers of cytochrome P450 mediated drug metabolism Immunocompromised subjects
Sites / Locations
- Enanta Pharmaceuticals, Inc.Recruiting